How much do the public sector and the private sector contribute to biopharmaceutical R&D?. Issue 4 (April 2022)

• Record Type: Journal Article
• Authors: Simoens, Steven; Huys, Isabelle
• Is Part Of: Drug discovery today. Volume 27:Issue 4(2022)
• Page Start: 939
• Page End: 945
• Publication Date: 2022-04
• Subjects: Biopharmaceutical R&D -- Public sector -- Private sector -- Investment -- Contribution; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2021.11.027
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: The contributions of the private and public sectors to biopharmaceutical R&D are interwoven. The public sector predominantly focuses on basic research. The private sector mainly targets medicine discovery and development. Public-sector investment generates additional private-sector investment. Abstract: When examining the prices of new medicines, the question of how much the private and public sectors have contributed to their R&D is often raised. Contributions can be assessed in terms of the investment, authorship of publications, marketing authorizations and intellectual property rights associated with biopharmaceutical R&D. This review of the empirical evidence underlines the complementary and interwoven nature of the private and public sectors in supporting biopharmaceutical R&D. Both sectors invest in and contribute to biopharmaceutical R&D, with the public sector predominantly focusing on basic research and the private sector mainly targeting medicine discovery and development. Public-sector investment generates additional private-sector investment.